Who is sponsoring BECONNEC?

BECONNEC is sponsored by University Hospital, Limoges.

What condition does BECONNEC study?

BECONNEC studies Corneal Newvessels.

What drugs are being tested in BECONNEC?

Interventions: bevacizumab, NaCl.

What is the status of BECONNEC?

BECONNEC is currently COMPLETED.

Last reviewed 2019-10-23 · How we verify

Effect of Bevacizumab Subconjunctival Injections on Corneal Newvessels (BECONNEC)

NCT01501760 Phase 3 COMPLETED

Corneal newvessels may arise from a fan of pathologies, inducing long-standing corneal opacification requiring keratoplasty. These last years, VEGF inhibitors have been designed to reduce newascularization induced by gastric cancer or age-related macular degeneration. A few reports have been published showing the interest of VEGF inhibitors to treat corneal newvessels, but no randomized study has been achieved to date. This study is designed to assess the efficacy of Bevacizumab, a VEGF inhibitor monoclonal antibody, to reduce the surface of corneal newvessels in when compared to placebo

Details

Lead sponsor	University Hospital, Limoges
Phase	Phase 3
Status	COMPLETED
Enrolment	38
Start date	2012-05-13
Completion	2019-10

Conditions

Corneal Newvessels

Interventions

bevacizumab
NaCl

Primary outcomes

Neovascularisation reduction at 3 months — at 3 months
Assessement using color photographs and a picture-analyser software that will calculate the percentage of corneal surface occupied by the newvessels at 3 months. A reduction of 30% is target.

Countries

France